A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly and Company
1,200 participants
May 15, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Eligibility
Inclusion Criteria3
- There are no specific eligibility criteria for the Master Protocol.
- See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes
- See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes
Interventions
Administered orally
Administered orally
Locations(80)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06993792